Flagship Founder and CEO Noubar Afeyan was joined by Aviv Regev, Executive Vice President at Genentech Research and Early Development (gRED) for a fascinating discussion on the intersection of AI and biology, the future of R&D, and the leaps in store for biomedicine. More from Flagship @ JPM2023 here.
More from:
Human Health
Pioneering Partnerships: Accelerating our Collaboration with Pfizer
Unlocking Therapeutic Breakthroughs with the Power of Platform Technologies
Halting the Trajectory of Disease with Preemptive Health
AI in Action
2025 CEO Chat: Torben Straight Nissen, CEO of Repertoire Immune Medicines
